Skip to main content

Lumify FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 13, 2021.

FDA Approved: Yes (First approved December 22, 2017)
Brand name: Lumify
Generic name: brimonidine tartrate
Dosage form: Ophthalmic Solution
Company: Bausch & Lomb Inc.
Treatment for: Ocular Redness

Lumify (brimonidine tartrate) is an over-the-counter (OTC) formulation of the alpha-adrenergic agonist brimonidine indicated for use in the treatment of ocular redness.

Brimonidine was first approved by the FDA in 1996 at higher doses for the reduction of intraocular pressure in glaucoma patients. Lumify is a lower dose brimonidine formulation intended to treat ocular redness by selectively constricting veins in the eye, increasing the availability of oxygen to surrounding tissue, and thereby reducing the potential risk of these side effects.

Development Timeline for Lumify

Dec 22, 2017Approval  Bausch + Lomb Receives FDA Approval of Lumify (brimonidine tartrate) Over-the-Counter Eye Drop for the Treatment of Eye Redness

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.